ArticleIBRO neuroscience reports2026
Lithium's effects on serum neurofilament light in Parkinson's disease: A post hoc analysis.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lithium as a Potential Neuroprotective Strategy in Glaucoma: Mechanisms and Therapeutic Perspectives.Biomolecules · 2026Review
- The LATTICE Study: Design of a pilot feasibility randomized controlled trial of lithium to delay cognitive decline in mild cognitive impairment.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serum neurofilament light chain (NfL) reflects neuronal degeneration and is likely a disease-progression biomarker in Parkinson's disease (PD). Therapies shown to decrease serum NfL in PD may provide disease-modifying effects. Serum glial fibrillary acidic protein (GFAP) may predict more rapid cognitive decline in PD. Methods: Serum samples from two PD trials were assessed for NfL and GFAP using the SIMOA platform at baseline and after 24-weeks of lithium therapy. Post hoc, patients were divided into three groups defined by their serum lithium levels at week 24: "high lithium" (0.21-0.56 mmol/L, median=0.32 mmol/L, Results: Median % 24-week changes in serum NfL were -12.8, -2.0 and 11.2 in the high, medium and low lithium groups, respectively. Pairwise group comparisons showed significant differences between high and low lithium ( Conclusion: In this post hoc analysis from two small clinical trials, lithium aspartate therapy achieving a median serum lithium level of 0.32 mmol/L was associated with a significant reduction in serum NfL in PD. Because serum NfL is likely a disease-progression biomarker in PD, further clinical investigation of lithium's effects on serum NfL and potential disease-modifying effects in PD is merited. Conclusion: "High lithium" therapy, achieving a median serum level of 0.32 mmol/L, was associated with a significant reduction in serum NfL in PD. Because serum NfL is likely a disease-progression biomarker in PD, further research is merited on lithium's potential disease-modifying effects in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.